H-20, Hymenochirin-1B [D9K;E6,N10,A18,A22 S5]

General Information


DRACP ID  DRACP02898

Peptide Name   H-20, Hymenochirin-1B [D9K;E6,N10,A18,A22 S5]

Sequence  IKLSPⓍTKKⓍLKKVLKGⓍIKGⓍIAVAKMV

Sequence Length  29

UniProt ID  W8PRC4 

PubChem CID  Not available

Origin  Synthetic (Derived from Hymenochirin-1B)

Type  Synthetic peptide

Classification

  

Active ACP Stapled Peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=2.10±0.32 μM MTT assay 96 h 1
HCT 116 Colon carcinoma Carcinoma IC50=2.63±0.35 μM MTT assay 96 h 1
HepG2 Hepatoblastoma Blastoma IC50=4.93±0.53 μM MTT assay 96 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Stapled: Ⓧ(6) and Ⓧ (10), Ⓧ(18) and Ⓧ (22) are cross-linked by hydrocarbon stapling

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  Ⓧ=(S)-N-Fmoc-2-(4′-pentenyl)alanine

Chiral  L



Physicochemical Information


Formula  C126H227N33O24S

Absent amino acids  CDEFHNQRWY

Common amino acids  K

Mass  356008

Pl  11.65

Basic residues  8

Acidic residues  0

Hydrophobic residues  11

Net charge  8

Boman Index  -88

Hydrophobicity  27.24

Aliphatic Index  117.59

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30789695

Title  Improving Selectivity, Proteolytic Stability, and Antitumor Activity of Hymenochirin-1B: A Novel Glycosylated Staple Strategy

Doi 10.1021/acschembio.9b00046

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_18020

DRACP is developed by Dr.Zheng's team.